Don't miss out on this exciting session, 'Hypertension, Liver, & Inflammation' at #HID24 .

Join us in June and earn #CME . Register at heartindiabetes.com/registration

@DLBhattMD Prof. Christos S. Mantzoros, MD, DSc, PHD Harvard Medical School Boston U Chobanian & Avedisian School of Medicine American Heart Association Brigham and Women's Hospital Cardiology Today #MedEd #CME #Metabolism

A heartfelt welcome is extended to our respected colleague, Akshay Desai as our final speaker for the 8th HID Dinner CME Symposium: Comorbidities of DM & CRM Diagnosis & Management.

Register now at heartindiabetes.com/registration !

#HID24 Brigham and Women's Hospital Harvard Medical School Cardiology Today

Join us at the 22nd Annual #WCIRDC2024 . Earn #CME credits in-person OR on-demand from December 12-14, 2024 at the Hilton Universal Hotel in Los Angeles.

Register now and secure #EarlyBird rates only available until May 31st at wcir.org/registration-2…

#MedEd #CardioMetabolic

We are honored to welcome our renowned colleague, Anjay Rastogi, MD, PhD, as our second speaker for the 8th HID Dinner CME Symposium: Comorbidities of DM & CRM Diagnosis & Management.

Register at heartindiabetes.com/registration & don't miss out on this incredible session!

#CME #HID2024

We welcome our esteemed colleague, Mark E. Cooper, AO, MBBS, PhD, as a speaker for the 8th HID Dinner CME Symposium: Comorbidities of DM & CRM Diagnosis & Management.

Register now at heartindiabetes.com/registration so you don't miss out on this exciting session!

#MedEd #HID2024 #CME

We’ve met the enrollment target in our pivotal Phase 3 PREVAIL CVOT and, driven by strong interest globally, expect to randomize more than 9,000 patients with a history of ASCVD. bit.ly/3TTqpAs

Big day today for patients with elevated Triglycerides with reduction in apo C-III, TG and pancreatitis. And a double whammy for our group and Ionis. 2 important trials presented and 2 back-to-back NEJM papers!. Big thanks to Brian Bergmark and Erik Stroes. Can it get…

A median 63.4% reduction in LDL-C was observed in patients receiving a combination of our potent CETP inhibitor, obicetrapib, and ezetimibe on top of high-intensity statins in our Phase 2 ROSE2 study. Our pivotal Phase 3 trial, TANDEM, will evaluate a fixed-dose combination of…

Join us for 8th HID - 2024 Lunch Session Non CME - Lilly Product Theater - Mounjaro® (tirzepatide) .

Register now for #Discounted rates available until April 30th at heartindiabetes.com/registration

(This session is not available for Continuing Medical Education Credits.)

#HID2024

So important to understand the value of Epicardial fat on CAC scans - authors.elsevier.com/sd/article/S26…
AJPC

I was 39 when I had a heart attack, and it took me over a decade to get the information I needed to understand that high lipoprotein(a) was a contributing factor. Unfortunately, this is an all too common story. #KnowLpa @thefhfoundation

Read my story:
FamilyHeart.org/genetics-heart…

#KnowLpa
Only 1%?? Need to do better!

So important metric of visceral fat. Easily measured on CAC scan authors.elsevier.com/sd/article/S26…

This metric and report card is a bad joke as a quality metric. It is chosen by every service at Baylor and even surgery got an A. Not evidence based, must be changed Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 National Lipid Association ASPC Dan Soffer BCM Cardiology vijay nambi Layla Abushamat

Now, FDA announces that bempedoic acid is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy in established cardiovascular disease or at high risk for a CVD event based on CLEAR Outcomes

Gregg Fonarow MD Boback Ziaeian 🤦🏻‍♂️ Sadiya Khan Clyde Yancy, MD, MSc Roger Blumenthal JACC Journals Dr. Deepak L. Bhatt A pivot toward establishment of sustainable rapid #GDMT implementation programs is critical. These should focus not only on advanced HF clinics but particularly on general cardiology and primary care environments. Go where the patients are!

#GDMT works

Is It Time to Rethink the Glucose Management Indicator? medscape.com/viewarticle/10… via @medscape

ADA Professional Publications JHU Welch Center Johns Hopkins Epidemiology

sdLDL particles are more likely to get trapped in the arterial wall, leading to atherosclerosis. In NewAmsterdam Pharma's ROSE2 clinical trial, patients receiving a combination of obicetrapib & ezetimibe achieved a >95% median reduction in small LDL-P levels. bit.ly/4coT5tt

For Women's Month, we celebrate these brilliant women who have shared their expertise in pursuit of medical education. See more exceptional women featured in this year's conference. #8thHeartInDiabetes #womensmonth

Register today, visit: heartindiabetes.com/registration